



Complete Summary

GUIDELINE TITLE

Hematemesis.

BIBLIOGRAPHIC SOURCE(S)

Gomes AS, Yucel EK, Bettmann MA, Casciani T, Grollman JH, Holtzman SR, Polak JF, Sacks D, Schoepf UJ, Stanford W, Jaff M, Moneta GL, Expert Panel on Cardiovascular Imaging. Hematemesis. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. 7 p. [50 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American College of Radiology (ACR), Expert Panel on Cardiovascular Imaging. Hematemesis. Reston (VA): American College of Radiology (ACR); 2002. 7 p. (ACR appropriateness criteria).

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Hematemesis

GUIDELINE CATEGORY

Diagnosis

CLINICAL SPECIALTY

Emergency Medicine
Family Practice
Gastroenterology
Internal Medicine
Radiology

INTENDED USERS

Health Plans
Hospitals
Managed Care Organizations
Physicians
Utilization Management

GUIDELINE OBJECTIVE(S)

To evaluate the appropriateness of initial radiologic examinations for patients with hematemesis

TARGET POPULATION

Patients with hematemesis

INTERVENTIONS AND PRACTICES CONSIDERED

1. X-ray
 - Chest
 - Esophagus and stomach with barium swallow, and upper gastrointestinal (GI) series
2. Invasive (INV)
 - Abdominal arteriography
 - Wedge hepatic venography
 - Splenoportography
3. Hepatic Doppler ultrasound
4. Computed tomography (CT)
 - Abdominal
 - Chest
5. Nuclear medicine
 - Technetium 99m (Tc-99m) labeled red blood cell (RBC) scan
 - Tc-99m sulfur colloid scan
6. Magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA)/magnetic resonance venography (MRV)

MAJOR OUTCOMES CONSIDERED

Utility of radiologic examinations in differential diagnosis

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The guideline developer performed literature searches of peer-reviewed medical journals, and the major applicable articles were identified and collected.

NUMBER OF SOURCE DOCUMENTS

The total number of source documents identified as the result of the literature search is not known.

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Not Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not stated

METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses
Systematic Review with Evidence Tables

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

One or two topic leaders within a panel assume the responsibility of developing an evidence table for each clinical condition, based on analysis of the current literature. These tables serve as a basis for developing a narrative specific to each clinical condition.

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus (Delphi)

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Since data available from existing scientific studies are usually insufficient for meta-analysis, broad-based consensus techniques are needed to reach agreement in the formulation of the appropriateness criteria. The American College of Radiology (ACR) Appropriateness Criteria panels use a modified Delphi technique to arrive at consensus. Serial surveys are conducted by distributing questionnaires to consolidate expert opinions within each panel. These questionnaires are

distributed to the participants along with the evidence table and narrative as developed by the topic leader(s). Questionnaires are completed by the participants in their own professional setting without influence of the other members. Voting is conducted using a scoring system from 1-9, indicating the least to the most appropriate imaging examination or therapeutic procedure. The survey results are collected, tabulated in anonymous fashion, and redistributed after each round. A maximum of three rounds is conducted and opinions are unified to the highest degree possible. Eighty percent agreement is considered a consensus. This modified Delphi technique enables individual, unbiased expression, is economical, easy to understand, and relatively simple to conduct.

If consensus cannot be reached by the Delphi technique, the panel is convened and group consensus techniques are utilized. The strengths and weaknesses of each test or procedure are discussed and consensus reached whenever possible. If "No consensus" appears in the rating column, reasons for this decision are added to the comment sections.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

ACR Appropriateness Criteria®

Clinical Condition: Hematemesis

Variant 1: History of alcoholism or liver disease.

Radiologic Exam Procedure	Appropriateness Rating	Comments
X-ray, chest	8	

Radiologic Exam Procedure	Appropriateness Rating	Comments
INV, abdomen, arteriography	6	
US, liver, Doppler	6	
CT, abdomen	6	
INV, liver, wedge venography	6	
NUC, liver, Tc-99m-labeled RBC scan	6	
MRI/MRA/MRV	6	MRI may be substituted for CT once the patient is stabilized.
CT, chest	4	
X-ray, esophagus and stomach, barium swallow, and upper GI series	4	
NUC, liver, Tc-99m sulfur colloid scan	4	
INV, splenoportography	2	
<p>Appropriateness Criteria Scale</p> <p>1 2 3 4 5 6 7 8 9</p> <p>1 = Least appropriate 9 = Most appropriate</p>		

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 2: No history of alcoholism or liver disease.

Radiologic Exam Procedure	Appropriateness Rating	Comments
INV, abdomen, arteriography	8	
X-ray, chest	8	
NUC, liver, Tc-99m sulfur colloid scan	6	
NUC, liver, Tc-99m-	6	

Radiologic Exam Procedure	Appropriateness Rating	Comments
labeled RBC scan		
US, liver, Doppler	4	
CT, abdomen	4	
CT, chest	4	
X-ray, esophagus and stomach, barium swallow, and UGI series	4	
MRI/MRA/MRV	4	MRI may be substituted for CT once the patient is stabilized.
INV, liver, wedge venography	4	
INV, splenoportography	2	
<p align="center">Appropriateness Criteria Scale 1 2 3 4 5 6 7 8 9 1 = Least appropriate 9 = Most appropriate</p>		

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Hematemesis, the vomiting of blood, occurs after bleeding into the UGI tract--the esophagus, stomach, or upper small bowel proximal to the ligament of Treitz. Hematemesis may be bright red or darker as a result of conversion of hemoglobin by gastric acid. It is frequently associated with melena. Hematochezia usually indicates lower GI bleeding but can be seen with major UGI bleeding due to rapid passage of blood through the GI tract. Despite advances in medical care, the overall mortality from UGI bleeding over the past 40 years has remained constant at approximately 10.8%. Upper gastrointestinal bleeding accounts for 10,000 to 20,000 deaths per year in the United States. A major factor accounting for this persistent high mortality is the increasing proportion of elderly patients presenting with GI bleeding, many of whom have comorbid conditions.

In patients with GI bleeding, stabilizing of blood pressure and restoring of intravascular volume are the first priorities. Only then should an attempt be made to identify and arrest the cause of bleeding. A temporary nasogastric tube should be inserted to aspirate gastric contents. The color of the gastric aspirate has prognostic significance and patients with red blood per gastric aspirate and red blood per rectum have a 30% mortality rate. While the presence of blood in a nasogastric aspirate confirms an UGI source, a nonbloody aspirate occurs in 3% to 16% of patients with UGI bleeding.

A directed history may suggest the source of the bleeding. In 70 to 80% of patients with UGI bleeding, bleeding stops spontaneously. Peptic ulcer disease is the leading cause of UGI bleeding in most series. However, series consisting of inner-city populations show a greater proportion of erosive gastritis and varices. The American Society of Gastrointestinal Endoscopy (ASGE) survey on UGI bleeding noted the following disease incidences: duodenal ulcer (24.3%), gastric erosions (23.4%), gastric ulcer (21.3%), varices (10.3%), Mallory-Weiss tears (7.2%), esophagitis (6.3%), duodenitis (5.8%), neoplasm (2.9%), stomal marginal ulcer (1.8%), esophageal ulcer (1.7%), and other/miscellaneous including angiodysplasia or vascular malformations (6.8%).

The three most important diagnostic techniques in the investigation of UGI bleeding are endoscopy, angiography, and radionuclide studies. Endoscopy (esophagogastroduodenoscopy) should be the initial method to define and treat acutely bleeding lesions. Patients with UGI bleeding that is ongoing or of sufficient magnitude to produce changes in vital signs or require transfusion should undergo emergent endoscopy, which identifies the source of hemorrhage in about 95% of cases. The endoscopic diagnosis provides important prognostic information regarding the risk of rebleeding and mortality. The endoscopic appearance of an ulcer provides prognostic information regarding rebleeding, the need for surgery, the level of hospital care required, and mortality. Early endoscopy (within 24 hours of hospital presentation) has been shown to reduce resource use, decrease transfusion requirements, and shorten hospital stay. A second look endoscopy in patients with high-risk ulcer stigmata at the time of initial endoscopy may decrease bleeding rates, surgery, and cost.

With rapid bleeding, however, it may not be possible to adequately visualize the site of bleeding. With the exception of the proximal duodenum and distal ileum, upper and lower endoscopy does not visualize the small intestine. Push enteroscopy, double balloon enteroscopy, and capsule endoscopy allow visualization of the small bowel.

Endoscopic hemostatic therapy can be grouped into three categories: 1) injection of sclerosants and/or vasoconstrictors, 2) use of thermal coagulation techniques, and 3) mechanical methods such as band ligation and clips.

With bleeding ulcers, thermal devices can stop bleeding 90% of the time. Multipolar electrocoagulation, laser photocoagulation, and heater probe therapy control bleeding equally well; however, the laser probe is used less frequently because of its higher cost. A meta-analysis of trials of therapeutic endoscopy showed that all modalities (laser photocoagulation, multipolar coagulation, heater probe, and injection therapy) are effective in reducing risk of rebleeding and the need for emergency surgery.

With acute hemorrhagic gastritis, endoscopic therapy may be more difficult because of the potential for diffuse mucosal bleeding.

Barium studies have no role in the evaluation of acute UGI bleeding. Technically adequate studies may be difficult to obtain in critically ill patients. Barium in the GI tract obscures active extravasation and may interfere with subsequent endoscopy or angiography. In stabilized patients with chronic, slow, or intermittent bleeding, barium studies may have a role in identifying lesions as

potential sources of bleeding. Because endoscopy is more accurate than barium studies, it should always precede barium studies in the evaluation of chronic UGI bleeding.

Radionuclide scans are also used in the diagnosis of gastrointestinal bleeding. Two categories of radiopharmaceuticals are clinically useful: 1) agents that are rapidly cleared from the vascular space by a specific organ, such as Technetium-99m (Tc-99m) sulfur colloid and 2) agents that circulate for an extended period such as Tc-99m labeled red blood cells (RBC). Because the Tc-99m sulfur colloid is rapidly cleared from the circulation, the patient must be actively bleeding at the time of injection. Bleeding rates as low as 0.05 mL/min to 0.1 mL/min can be detected using radionuclide techniques. The Tc-99m labeled RBC study is the method most frequently used for the detection of GI bleeding. Imaging may be performed over a 24-hour period, which may be helpful in detecting of intermittent bleeding. The need for delayed imaging to identify a bleeding site introduces uncertainty with respect to location because antegrade and retrograde movement of intraluminal red cells can occur. Published reports differ in their enthusiasm for RBC scintigraphy, with some authors reporting high accuracy and others finding it inaccurate.

Early series reported sensitivities greater than 80% for the detection of bleeding with radionuclide scans, higher than those of arteriography. However, subsequent studies showed errors in localization of the bleeding site in up to 60% of cases. When the value of the scan in predicting a subsequent positive arteriogram was examined, patients had a nearly equal likelihood of having a positive or negative arteriogram regardless of the result of the Tc-99m RBC scan. In a study of 103 patients, of 85 patients with a bleeding site documented by arteriography, surgery, or endoscopy, only 15% of them had a positive Tc-99m RBC scan that correctly localized the bleeding, and the overall sensitivity of the radionuclide study for bleeding was only 20%. Overall, the accuracy of the Tc-99m RBC scan in localizing the site of GI bleeding ranges from 41% to 94% in the literature.

Most of the reported series include scans of both upper and lower GI bleeding. The most common errors in bleeding site localization occur from sources in the stomach, duodenum, and small bowel. This error in localization was often found to be attributable to rapid transit of blood and insufficient frequency of serial static imaging. The accuracy of the Tc-99m RBC scan is increased when the scan is positive within the first two hours in the continuous phase of the test. Most scintigraphy series included a substantial proportion of patients in whom endoscopy would be expected to identify the bleeding site. The successful use of endoscopy initially should leave only a small percentage of patients with UGI bleeding in whom nuclear medicine studies may be of value. The radionuclide techniques may be of more value in diagnosing of lower GI bleeding. For diagnosis of Meckel's diverticulum, scintigraphy with pertechnetate continues to be the most efficient technique.

When acute GI bleeding is intermittent, and endoscopy does not identify the lesion, angiography is often requested. If the patient is not actively bleeding, angiography will have a low yield. Consequently, in practice, the vascular radiologist may defer angiography until a radionuclide study has been performed. If there is evidence of bleeding on the radionuclide study, this affords the angiographer some confidence that the study will have a chance of detecting the

offending vessel. It further assists in the timing of angiography. If there is no active bleeding, angiography does not have to be performed on an emergency basis. However, in patients with uncontrolled continual active hemorrhage, delaying angiography for scintigraphy is not warranted. Arteriography may still be indicated, as it may reveal a structural lesion that bleeds intermittently.

Arteriography is used in the diagnosis of both acute and chronic bleeding and in the treatment of GI bleeding. It is indicated when endoscopy is negative or unsuccessful in controlling bleeding. The accuracy of diagnostic arteriography for detecting a bleeding source is increased if there is active bleeding. Visceral arteriography has sensitivity for identifying active hemorrhage at a minimal rate of 0.5 mL/min. Only arterial or capillary bleeding can be detected by selective visceral arteriography; venous bleeding is rarely, if ever, detected on the venous phase of an arteriogram. With variceal hemorrhage, varices can be demonstrated, but the role of angiography in this setting is primarily to rule out a concomitant source of arterial bleeding and to define vascular anatomy.

Arteriography is also indicated in patients with chronic intermittent bleeding of obscure origin in whom all other modalities are unrevealing. In one study, the source of bleeding was established by arteriography in 44% of such patients. Repeat arteriography in patients with continued bleeding following an initially negative angiogram has been shown to be diagnostic in 25% of cases. Subselective catheterization of the bleeding vessel at time of arteriography with injection of methylene blue can facilitate intraoperative identification of the bleeding bowel segment.

Selective arterial catheterization can be used to deliver local therapy such as vasopressin infusion or embolization. In patients with gastric mucosal bleeding, selective vasopressin infusion is associated with an overall bleeding control rate of 72% and a bleeding recurrence rate of 18%. Vasopressin is less effective in controlling pyloroduodenal, hepatic, or pancreatic bed bleeding with control rates of 31% to 42% and rebleeding rates of 25% to 33%. This is attributed, among other factors, to the dual vascular supply in the duodenum. Small-bowel hemorrhage has been reported to be controlled with intra-arterial vasopressin in 71% of patients. The use of vasopressin infusion has largely been supplanted by transcatheter embolization therapy.

Transcatheter arterial embolization therapy is now the primary radiographic treatment for nonvariceal upper GI bleeding and has a high technical success rate. It has been associated with lower complication rates than have been reported with vasopressin.

Vascular embolization can be used for virtually all arterial or arteriocapillary bleeding sources in the UGI tract. In patients with prior surgery, the collateral supply should be assessed. Success in controlling duodenal hemorrhage by embolotherapy ranges from 60% to 100%. Transcatheter embolization therapy is also of benefit in patients with mesenteric bleeding. A variety of embolic agents are used. Microcoils, alone or in combination with gelatin sponge particles or polyvinyl alcohol sponge particles or hydrogel spheres are effective embolic agents. Neither absolute alcohol nor gelfoam powder is recommended due to distal penetration of these agents.

Bleeding Due to Portal Hypertension

Although most portal hypertensive bleeds result from ruptured distal esophageal varices, bleeding from other sources such as gastric varices, portal hypertensive gastropathy, and ectopic varices can occur. As with nonvariceal bleeding, prompt resuscitation of the patient is necessary. Lung aspiration of gastric contents is a major concern, especially in encephalopathic patients, and endotracheal intubation is often used in patients at risk for aspiration. Esophageal varices form only when the hepatic vein pressure gradient exceeds 12 mm Hg and variceal hemorrhage typically does not occur until the hepatic vein pressure gradient exceeds 12 mm Hg. Gastric varices, however, may bleed at a lower pressure gradient. Endoscopy is indicated to determine the site and activity of bleeding. One third to one half of bleeding cirrhotics are not bleeding from varices.

Endoscopic therapy is currently the treatment of choice for active variceal hemorrhage. Pharmacologic therapy to reduce portal pressure is a first-line therapy that can be administered emergently while awaiting endoscopy. Balloon tamponade is useful when pharmacologic and endoscopic treatment fail to produce stabilization prior to radiologic intervention or surgery. A variety of pharmacologic agents are available. These include vasopressin and its analogue terlipressin, somatostatin and its analogue octreotide, and nitrovasodilators. Vasopressin infusion has been reported to achieve hemostasis in 70 to 85% of patients, but approximately 30 to 50% of patients experienced early rebleeding. Somatostatin is more effective than placebo or vasopressin and has fewer cardiovascular side effects than vasopressin, but it is not readily available. Octreotide, a synthetic analogue of somatostatin with a longer half-life, has become the most widely used pharmacologic therapy for acute variceal hemorrhage and is the drug of choice in the United States. Terlipressin, which has fewer side effects than vasopressin and nitroglycerin combined, is comparable to somatostatin and octreotide, but is not available in the United States.

Balloon tamponade has been shown to be initially effective in 84 to 92% of patients; however, rebleeding is common after deflation or removal, occurring in 27 to 45% of patients. It is largely used as a rescue procedure so that patients can be stabilized for more definitive therapy. Endoscopic treatment is currently the treatment of choice for active variceal hemorrhage. Multiple randomized trials with subsequent meta-analysis have shown endoscopic sclerotherapy (EST) to be either superior to, or at least as effective as, pharmacologic therapy alone or in combination with balloon tamponade in the control of active hemorrhage. A meta-analysis of seven long-term studies suggested that EST when compared with medical therapy reduced mortality by 25%. Endoscopic sclerotherapy may be unsuccessful in 10 to 30% of patients, with recurrent bleeding occurring in as many as 30 to 50% of patients. Another concern is the high incidence of complications postsclerotherapy, which include bleeding, perforation, and stenosis with an associated 15% mortality rate. Endoscopic variceal ligation (EVL) has been found to be equally effective in controlling acute bleeding and is associated with fewer complications than EST. Therefore, band ligation is recommended as the preferred endoscopic therapy for acute variceal bleeding.

The portal venous system can be evaluated using a variety of imaging techniques. Arterial portography, direct transhepatic portal venography, transjugular portal venography, and splenoportography all permit evaluation of portal venous flow

patterns, which may aid preoperative shunt planning, detection of varices, and postoperative assessment of shunt patency. Splenoportography is infrequently used. Wedged hepatic venography is a useful index of portal venous pressure. Additional noninvasive imaging modalities—including color duplex Doppler ultrasound, CT, and MRI—also allow evaluation of the portal venous system, shunt patency, and liver parenchyma. They frequently replace the invasive procedures.

Percutaneous transcatheter embolization of the coronary vein and esophageal varices has been shown to control variceal bleeding in 83% of patients; however, bleeding recurs in 55% of surviving patients at six months and in 66% at one year. Because recurrent bleeding is a common problem, this technique is no longer widely used.

Approximately 10 to 20% of patients fail to stop bleeding or rebleed following endoscopic treatment. A second attempt at endoscopic therapy may be successful; however, if it is unsuccessful, alternative therapy is recommended, since when two attempts at hemostasis fail, the risk of mortality is high. Surgical shunt procedures are effective in stopping initial bleeding and preventing rebleeding; however, emergency surgery is associated with an approximately 50% mortality in poor operative candidates. The lack of available donor organs precludes the emergency use of liver transplantation for patients with end-stage liver disease who develop acute variceal hemorrhage.

The transjugular intrahepatic portosystemic shunt (TIPS) procedure has been shown to effectively stop variceal bleeding unresponsive to endoscopic therapy. Numerous studies have shown it to be of benefit in the management of patients with esophageal varices who have failed pharmacologic and endoscopic therapy and who are poor surgical candidates. The incidence of rebleeding following TIPS is approximately 16 to 30% in late follow-up because of stent stenosis primarily due to neointimal hyperplasia. Shunt patency can usually be restored with angioplasty or additional stents. Therefore, TIPS patency should be monitored with periodic Doppler ultrasound or venography. TIPS is also effective for treatment of refractory bleeding from gastric and ectopic variceal bleeding and prevention of rebleeding in these patients. TIPS is also useful in the management of patients with portal hypertensive gastropathy who have failed endoscopic and medical treatment. It has not been shown effective in gastric antral ectasia (GAVE).

Bleeding Due to Hemobilia

Hemobilia has been observed with increasing frequency because of the greater use of percutaneous transhepatic procedures. Upper endoscopy may demonstrate blood from the ampulla, but this does not specify the site or cause of the hemorrhage. Surgical ligation of the main hepatic artery or partial hepatectomy were previously the treatments of choice, but have been replaced by selective hepatic arteriography with therapeutic embolization in those cases due to hepatic artery bleeding. With biliary venous fistulae associated with percutaneous transhepatic tubes, tube replacement with embolization of the tube tract is useful.

New Techniques

Helical CT after intra-arterial injection of contrast media has been reported to improve the detection of GI bleeding.

Abbreviations

- CT, computed tomography
- GI, gastrointestinal
- INV, invasive
- MRA, magnetic resonance angiography
- MRI, magnetic resonance imaging
- MRV, magnetic resonance venography
- NUC, nuclear medicine
- RBC, red blood cell
- Tc-99m, Technetium 99 metastable
- UGI, upper gastrointestinal
- US, ultrasound

CLINICAL ALGORITHM(S)

Algorithms were not developed from criteria guidelines.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are based on analysis of the current literature and expert panel consensus.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Selection of appropriate radiologic imaging procedures for evaluation of patients with hematemesis

POTENTIAL HARMS

Not stated

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

An American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should

dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Personal Digital Assistant (PDA) Downloads

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Gomes AS, Yucel EK, Bettmann MA, Casciani T, Grollman JH, Holtzman SR, Polak JF, Sacks D, Schoepf UJ, Stanford W, Jaff M, Moneta GL, Expert Panel on Cardiovascular Imaging. Hematemesis. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. 7 p. [50 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1998 (revised 2006)

GUIDELINE DEVELOPER(S)

American College of Radiology - Medical Specialty Society

SOURCE(S) OF FUNDING

The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®.

GUIDELINE COMMITTEE

Committee on Appropriateness Criteria, Expert Panel on Cardiovascular Imaging

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Panel Members: Antoinette S. Gomes, MD; E. Kent Yucel, MD; Michael A. Bettmann, MD; Thomas Casciani, MD; Julius H. Grollman, MD; Stephen R. Holtzman, MD; Joseph F. Polak, MD, MPH; David Sacks, MD; U. Joseph Schoepf, MD; William Stanford, MD; Michael Jaff, MD; Gregory L. Moneta, MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American College of Radiology (ACR), Expert Panel on Cardiovascular Imaging. Hematemesis. Reston (VA): American College of Radiology (ACR); 2002. 7 p. (ACR appropriateness criteria).

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

GUIDELINE AVAILABILITY

Electronic copies: Available (in Portable Document Format [PDF]) from the [American College of Radiology \(ACR\) Web site](#).

ACR Appropriateness Criteria® Anytime, Anywhere™ (PDA application). Available from the [ACR Web site](#).

Print copies: Available from the American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. Telephone: (703) 648-8900.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- ACR Appropriateness Criteria®. Background and development. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on February 20, 2001. The information was verified by the guideline developer on March 14, 2001. This summary was updated by ECRI on March 31, 2003. The updated information was verified by the guideline developer on April 21, 2003. This summary was updated by ECRI on August 7, 2006.

COPYRIGHT STATEMENT

Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria® may be found on the [ACR Web site](#).

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 10/2/2006